Raytheon awarded $71 million in Navy contracts for missile systems
Investing.com - RBC Capital has raised its price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) to $151.00 from $145.00 while maintaining an Outperform rating on the stock. According to InvestingPro data, analysts remain bullish on JAZZ, with targets ranging from $147 to $230, suggesting significant upside potential from current levels.
The price target increase follows Jazz Pharmaceuticals’ investor call regarding its recently approved drug Modeyso, which treats rare H3 K27M mutant gliomas.
RBC Capital noted several positive factors including higher-than-expected pricing for Modeyso, Jazz’s committed launch strategy with 50 representatives already deployed, and a highly motivated patient and prescriber base.
Despite acknowledging potential challenges in patient identification, RBC Capital projects Modeyso could achieve approximately $500 million in peak sales based on the strength of other rare oncology drug launches.
The investment firm indicated it believes the market is currently undervaluing Jazz Pharmaceuticals’ near-term cash flows and upcoming catalysts.
In other recent news, Jazz Pharmaceuticals reported its second-quarter earnings for 2025, which showed a greater loss per share than analysts had anticipated. The company posted an EPS of -8.25, whereas the expected figure was -7.62. Despite the earnings miss, Jazz Pharmaceuticals’ revenue slightly exceeded projections, coming in at $1.05 billion. Additionally, Jazz Pharmaceuticals has officially launched Modeyso, a treatment for recurrent H3 K27M-mutant diffuse midline glioma, a rare pediatric brain tumor. Stifel has reiterated a Buy rating for the company, maintaining a price target of $230.00. The firm highlighted Modeyso as the first approved treatment for this aggressive condition, suggesting it could become the standard of care due to the lack of alternatives. These developments are part of the company’s recent activities and have garnered attention from investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.